(Press-News.org) Los Angeles, CA (October 11, 2010) NFL players with concussions now stay away from the game significantly longer than they did in the late 1990s and early 2000s, according to research in Sports Health (owned by American Orthopaedic Society for Sports Medicine and published by SAGE). The mean days lost with concussion increased from 1.92 days during 1996-2001 to 4.73 days during 2002-2007.
In an effort to discover whether concussion injury occurrence and treatment had changed, researchers compared those two consecutive six-year periods to determine the circumstances of the injury, the patterns of symptoms, and a player's time lost from NFL participation. Those time periods were chosen because concussion statistics were recorded by NFL teams using the same standardized form. It recorded player position, type of play, concussion signs and symptoms, loss of consciousness and medical action taken.
Researchers found that in 2002-2007 there were fewer documented concussions per NFL game overall, especially among quarterbacks and wide receivers. But there was a significant increase in concussions among tight ends. Symptoms most frequently reported included headaches, dizziness, and problems with information processing and recall.
Significantly fewer concussed players returned to the same game in 2002-2007 than in 1996-2001 and 8% fewer players returned to play in less than a week. That number jumped to 25% for those players who lost consciousness as a result of the injury.
"There are a number of possible explanations for the decrease in percentages of players returning to play immediately and returning to play on the day of the injury as well as the increased days out after (a concussion) during the recent six year period compared to the first six year period," write authors Ira R. Casson, M.D.; David C. Viano, Dr. med.; Ph.D., John W. Powell, Ph.D.; and Elliot J. Pellman, M.D. "These include the possibility of increased concussion severity, increased player willingness to report symptoms to medical staff, adoption of a more cautious conservative approach to concussion management by team medical personnel and a possible effect of changes in neuropsychological (NP) testing."
INFORMATION:
The article "Twelve Years of NFL Concussion Data" in the Nov/Dec 2010 issue of Sports Health, is available free for a limited time at http://sph.sagepub.com/content/early/2010/10/01/1941738110383963.full.pdf+html.
Sports Health: A Multidisciplinary Approach publishes review and original research articles, case studies and more for professionals involved in the training and care of the competitive or recreational athlete. Sports Health is a collaborative, bimonthly publication from the American Orthopaedic Society for Sports Medicine (AOSSM), the American Academy of Pediatrics, the American Medical Society for Sports Medicine (AMSSM), the American Osteopathic Academy of Sports Medicine, the National Athletic Trainers' Association (NATA), and the Sports Physical Therapy Section (SPTS), Sports Health. www.sportshealthjournal.org
SAGE is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students spanning a wide range of subject areas including business, humanities, social sciences, and science, technology, and medicine. An independent company, SAGE has principal offices in Los Angeles, London, New Delhi, Singapore and Washington DC. www.sagepublications.com
NFL players with concussions now sidelined longer
2010-10-13
ELSE PRESS RELEASES FROM THIS DATE:
Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer
2010-10-13
Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.
"This is a major step forward in prostate cancer therapeutics," said Dr Johann de Bono from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in London, who presented the study results at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. "Patients in this Phase-III ...
Fertility concerns of cancer survivors inadequately addressed, study finds
2010-10-13
Many cancer survivors experience changes in sexual function that leave them feeling guilty and a longing for intimacy, Australian researchers told at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The researchers say that these sexuality and fertility concerns are often not adequately addressed by doctors.
Professor Bogda Koczwara from Flinders Medical Centre in Adelaide said that fertility concerns among cancer survivors was a growing problem, due to a combination of improved cancer treatment outcomes in young cancer survivors ...
Re-evaluating the time of your life
2010-10-13
In life, we're told, we must take the good with the bad, and how we view these life events determines our well-being and ability to adjust. But according to Prof. Dov Shmotkin of Tel Aviv University's Department of Psychology, you need more than the right attitude to successfully negotiate the vicissitudes of life.
As recently reported in Aging and Mental Health, Prof. Shmotkin's research reveals that people's well-being and their adaptation can be ascertained by their "time trajectory" ― their concept of how they have evolved through their remembered past, currently ...
Sexual issues a major concern for cancer patients taking new targeted drugs
2010-10-13
New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient's sex life, researchers have found.
At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of cancer therapy on the sexual functioning of patients.
Dr Yohann Loriot and Dr Thomas Bessede from Institut Gustave Roussy in Villejuif, France and colleagues found that patients taking ...
Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
2010-10-13
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Vincent Miller from Memorial Sloan-Kettering Cancer Center in New York, USA, reported findings from the LUX-Lung 1 trial of afatinib in 585 patients with lung adenocarcinoma whose cancer had progressed after chemotherapy ...
New Phase II study shows first-line promise of lung cancer drug PF-299
2010-10-13
A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO).
Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have remained progression-free for at least nine months, reported Dr Tony Mok from the Chinese University of Hong Kong.
While some ...
Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer
2010-10-13
An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
Urothelial cancers affect the tissue lining the inner surfaces of the bladder and other parts of the urinary system. In cases of metastatic disease, median survival is approximately 12-15 months and there is a 10-15% chance of prolonging it by the use of standard chemotherapy regimens, particularly in otherwise healthy ...
Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
2010-10-13
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.
At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charité University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors.
Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine ...
Selective strategy could lead to new approaches against schizophrenia
2010-10-13
A new class of compounds identified by researchers at Emory University School of Medicine could be developed into drugs for the treatment of schizophrenia. The compounds enhance signaling by molecules in the brain called NMDA receptors, which scientists believe are functioning at low levels in people with schizophrenia.
Led by Stephen Traynelis, PhD, professor of pharmacology, a team of Emory researchers sifted through thousands of chemicals and found one, called CIQ, which could selectively enhance the function of certain NMDA receptors without affecting others.
The ...
A picture worth a thousand words: New research links visual cues to male sexual memory
2010-10-13
Iowa City, IA—October 11, 2010— A new study published in Applied Cognitive Psychology finds that college-aged men are very likely to remember a woman's initial sexual interest (attraction or rejection), especially when the woman in question is thought to be attractive, is dressed more provocatively, and expresses positive sexual interest.
In the study the men were shown full-body photographs of college-aged women who expressed cues of sexual interest or rejection. The participating males represented mixed sexual histories, and a capacity for varying degrees of sexually ...